Skip to content
  • ENGLISHENGLISH
  • 繁體中文繁體中文
回首頁回首頁回首頁
  • About Alar
    • Company Profile
    • Leadership Team
    • History & Milestones
  • Products
    • Product Pipeline
    • Contract Manufacturing
  • Media
    • News
    • Events
  • Investors
    • Stock Info
    • Financials
  • Contact Us
MENU Close

2022/11/21 ALA-1000 received notice of patent allowance from China National Intellectual  Property Administration, Application No. 201780055635.3

2022/11/21 ALA-1000 received notice of patent allowance from China National Intellectual  Property Administration, Application No. 201780055635.3

  • Post author:alarpharm
  • Post published:21 . 11 . 2022
  • Post category:Media releases

You Might Also Like

2022/05/12 ALA-1000 Received notice of patent allowance from Director de Invenciones y Nuevas Tecnologías INDECOPI , Application No. 000487-2019/DIN.

13 . 5 . 2022

2021/10/28 Alar Pharmaceuticals Inc. Completes Successful End-of-Phase 2 Meeting with US FDA for ALA-1000 for the Treatment of Opioid Use Disorder

28 . 10 . 2021

2021/05/10 ALA-1000 Receive notice of patent allowance from Innovation, Science and Economic Development Canada (ISED), Application No.3,033,046

8 . 6 . 2021

2021/04/16 ALA-1000 Receive notice of allowance for patent registration from Korean Intellectual Property Office (Application No. 10-2019-7009185).

21 . 4 . 2021

2023/07/19 ALA-1300 Received the patent, LONG-ACTING INJECTABLE FORMULATIONS AND CRYSTALLINE FORMS OF BUPRENORPHINE DERIVATIVES , from Directorate General of Intellectual Property Rights (DGIP) of Indonesia, NO IDP 000 087828 B

26 . 7 . 2023
  • News
  • Events
回首頁

ABOUT

  • Company Profile
  • Leadership Team
  • History & Milestones
  • Company Profile
  • Leadership Team
  • History & Milestones

PRODUCTS

  • Product Pipeline
  • Contract Manufacturing
  • Product Pipeline
  • Contract Manufacturing

MEDIA

  • News
  • Events
  • News
  • Events

INVESTORS

  • Stock Info
  • Financials
  • Stock Info
  • Financials

CONTACT US

  • Contact Us
  • Contact Us
  • Contact Us
  • Privacy Policy
Copyright © - 2022 Alar Pharmaceuticals Inc . All right reserved.
Close
  • About Alar
    • Company Profile
    • Leadership Team
    • History&Milestones
  • Products
    • Products Pipeline
    • Contract Manufacturing
  • Media
    • News
    • Events
  • Investors
    • Stock Info
    • Financials
  • Contact Us
    • Contact Us
×

Cart